Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) receptor , is demonstrating promising outcomes in preliminary clinical studies. Current https://artybookmarks.com/story21181277/retatrutide-emerging-research-and-potential-therapeutic-roles